Source: https://www.fichier-pdf.fr/2016/11/23/ransohoff2016science/
Timestamp: 2019-04-18 14:39:18+00:00

Document:
Ce document au format PDF 1.4 a été généré par Arbortext Advanced Print Publisher 9.1.440/W Unicode / Acrobat Distiller 5.0.5 (Windows), et a été envoyé sur fichier-pdf.fr le 23/11/2016 à 17:26, depuis l'adresse IP 109.8.x.x. La présente page de téléchargement du fichier a été vue 381 fois.
Taille du document: 804 Ko (8 pages).
endow it with its distinctive functions. ConnecBiogen, 225 Binney Street, Cambridge, MA 02142, USA.
comprising 1015 connections in all.
challenging to understand and treat: No therapeutics ameliorate the natural course of neurodegenerative disease.
Behav. Immun. 56, 187–196 (2016).
43. B. Tang, H. Jia, R. J. Kast, E. A. Thomas, Brain Behav. Immun.
44. C. M. Connor et al., Schizophr. Res. 140, 175–184 (2012).
JAMA Psychiatr. 70, 677–685 (2013).
47. M. Ronovsky, S. Berger, B. Molz, A. Berger, D. D. Pollak, Curr.
48. U. Meyer, J. Feldon, O. Dammann, Pediatr. Res. 69, 26R–33R (2011).
49. S. H. Lee et al., Nat. Genet. 45, 984–994 (2013).
50. A. M. Depino, Neuroscience 299, 56–65 (2015).
51. D. Krstic et al., J. Neuroinflammation 9, 151 (2012).
52. A. Malishkevich et al., Transl. Psychiatry 5, e501 (2015).
53. K. Lepeta et al., J. Neurochem. (2016).
54. H. Wang, Front. Cell. Neurosci. 9, 43 (2015).
55. M. L. Estes, A. K. McAllister, Brain Pathol. 24, 623–630 (2014).
Ann. N. Y. Acad. Sci. 1107, 118–128 (2007).
Behav. Immun. 31, 54–68 (2013).
58. C. J. Shatz, Neuron 64, 40–45 (2009).
59. M. W. Glynn et al., Nat. Neurosci. 14, 442–451 (2011).
60. A. Sekar et al., Nature 530, 177–183 (2016).
61. G. Tang et al., Neuron 83, 1131–1143 (2014).
J. Neurosci. 33, 13791–13804 (2013).
63. I. Voineagu, V. Eapen, Front. Hum. Neurosci. 7, 738 (2013).
J. Neurosci. 34, 7988–7998 (2014).
65. Z. M. Ignácio et al., Br. J. Clin. Pharmacol. 2016, bcp.12845 (2016).
66. S. L. Hollins, K. Zavitsanou, F. R. Walker, M. J. Cairns, Transl.
67. A. M. Hemmerle et al., Schizophr. Res. 168, 411–420 (2015).
68. M. Sahin, M. Sur, Science 350, aab3897 (2015).
69. J. Y. Kim et al., Neuron 63, 761–773 (2009).
70. E. Santini, E. Klann, Sci. Signal. 7, re10 (2014).
71. J. Kipnis, Science 353, 766–771 (2016).
72. E. Y. Hsiao et al., Cell 155, 1451–1463 (2013).
73. L. K. Beura et al., Nature 532, 512–516 (2016).
74. Y. Yang et al., Nature 510, 152–156 (2014).
75. S. Giovanoli et al., Transl. Psychiatry 6, e772 (2016).
J. Neurosci. 27, 10695–10702 (2007).
Behav. Immun. 42, 178–190 (2014).
Behav. Immun. 26, 326–336 (2012).
79. P. Coyle, N. Tran, J. N. Fung, B. L. Summers, A. M. Rofe, Behav.
Brain Res. 197, 210–218 (2009).
81. Q. Li et al., Transl. Psychiatry 5, e641 (2015).
82. F. Lanté et al., Hippocampus 18, 602–609 (2008).
83. B. Clancy et al., Neuroinformatics 5, 79–94 (2007).
84. D. J. Dowling, O. Levy, Trends Immunol. 35, 299–310 (2014).
Table 1. Protein aggregates in neurodegenerative diseases. A-b, N-terminal amyloidogenic fragments of APP; MAPT, microtubule-associated protein tau; TDP-43, 43-kDa TAR DNA-binding protein.
Table 2. Selected elements of the CNS neuroinflammatory system.
various ways in each of these disorders (12).
intervention or topics for intensive investigation.
through the early years of the 21st century.
neurons, provided support for this hypothesis (17).
well as neuronal Lewy bodies (25, 26).
applied incautiously to CNS glia (29).
Fig. 2. Pathways from microglial gene variants or altered gene expression to neurodegeneration.
are the neurodegenerative effects of CX3CR1 deficiency in hTau mice (middle column) (70) and complement dysregulation in a model of amyloid pathology (right column) (77).
activities were essential for brain homeostasis.
the dominant risk-associated gene, is mainly expressed in astrocytes and reactive microglia (34).
microarray expression profiles enables the pursuit of this research direction (34–36).
by yet-to-be-identified chance elements (80–82).
during demyelination and of chronic demyelination.
influx activates calcium-dependent enzymes, lysing the axon.
by neurologists, remains stable between relapses.
lacking the earlier phase of attacks and remissions.
(for astrocytes) (49) are required.
might stimulate amyloid deposition (56).
Target identification based on human-disease genetic validation enhances prospects for success.
methods for confirming “hits” are highly promising. Systems biology can make additional contributions to target prosecution.
peripheral inflammatory stimuli and the degradation of homeostasis caused by an impaired BBB.
of therapeutic success against these severe diseases.
R. Madabhushi, L. Pan, L. H. Tsai, Neuron 83, 266–282 (2014).
R. Lardenoije et al., Prog. Neurobiol. 131, 21–64 (2015).
G. G. Kovacs et al., Neuroscience 269, 152–172 (2014).
H. Leicht et al., PLOS ONE 8, e70018 (2013).
V. Chouraki, S. Seshadri, Adv. Genet. 87, 245–294 (2014).
M. Jucker, L. C. Walker, Nature 501, 45–51 (2013).
L. C. Walker, M. I. Diamond, K. E. Duff, B. T. Hyman, JAMA Neurol.
Nat. Rev. Neurosci. 16, 109–120 (2015).
D. J. Selkoe, J. Hardy, EMBO Mol. Med. 8, 595–608 (2016).
M. Redmann, V. Darley-Usmar, J. Zhang, Aging Dis. 7, 150–162 (2016).
J. Rogers et al., Neurobiol. Aging 17, 681–686 (1996).
B. A. in ‘t Veld et al., N. Engl. J. Med. 345, 1515–1521 (2001).
Cochrane Database Syst. Rev. 2, CD006378 (2012).
L. Qiang, R. Fujita, A. Abeliovich, Neuron 78, 957–969 (2013).
D. L. Price et al., Ann. N. Y. Acad. Sci. 920, 179–191 (2000).
S. Boillée et al., Science 312, 1389–1392 (2006).
K. Yamanaka et al., Nat. Neurosci. 11, 251–253 (2008).
C. S. Lobsiger, D. W. Cleveland, Nat. Neurosci. 10, 1355–1360 (2007).
X. L. Gu et al., Mol. Brain 3, 12 (2010).
during the inflammatory phase of disease (37, 38).
the vast majority of patients.
intrathecal inflammatory foci drive ongoing demyelination of underlying cortical tissue.
25. D. Brück, G. K. Wenning, N. Stefanova, L. Fellner, Neurobiol. Dis.
Acta Neuropathol. 121, 675–693 (2011).
27. O. Butovsky et al., Nat. Neurosci. 17, 131–143 (2014).
28. R. M. Ransohoff, V. H. Perry, Annu. Rev. Immunol. 27, 119–145 (2009).
29. R. M. Ransohoff, Nat. Neurosci. 19, 987–991 (2016).
30. M. M. Bianchin et al., Cell. Mol. Neurobiol. 24, 1–24 (2004).
31. J. Walter, J. Biol. Chem. 291, 4334–4341 (2016).
32. R. E. Tanzi, N. Engl. J. Med. 372, 2564–2565 (2015).
J. M. Pocock, Curr. Opin. Neurobiol. 36, 74–81 (2016).
35. I. R. Holtman et al., Glia 63, 1495–1506 (2015).
36. Y. Zhang et al., J. Neurosci. 34, 11929–11947 (2014).
37. O. H. Kantarci et al., Ann. Neurol. 79, 288–294 (2016).
38. B. A. Cree, Handb. Clin. Neurol. 122, 211–230 (2014).
39. P. Patrikios et al., Brain 129, 3165–3172 (2006).
40. B. Kornek et al., Am. J. Pathol. 157, 267–276 (2000).
41. C. F. Lucchinetti et al., N. Engl. J. Med. 365, 2188–2197 (2011).
42. B. Obermeier et al., Nat. Med. 14, 688–693 (2008).
43. M. Absinta et al., Neurology 85, 18–28 (2015).
44. R. Magliozzi et al., Ann. Neurol. 68, 477–493 (2010).
45. H. Lui et al., Cell 165, 921–935 (2016).
46. J. R. Wendland, M. D. Ehlers, Biol. Psychiatry 79, 650–656 (2016).
47. A. Masuch et al., Glia 64, 1285–1297 (2016).
49. P. W. Zhang et al., Glia 64, 63–75 (2016).
50. A. E. Cardona et al., Nat. Neurosci. 9, 917–924 (2006).
51. D. Erny et al., Nat. Neurosci. 18, 965–977 (2015).
52. V. Rothhammer et al., Nat. Med. 22, 586–597 (2016).
53. C. Holmes et al., Neurology 73, 768–774 (2009).
55. R. D. Bell et al., Neuron 68, 409–427 (2010).
56. D. K. Kumar et al., Sci. Transl. Med. 8, 340ra72 (2016).
57. H. H. Klünemann et al., Neurology 64, 1502–1507 (2005).
58. C. N. Parkhurst et al., Cell 155, 1596–1609 (2013).
59. D. P. Schafer et al., Neuron 74, 691–705 (2012).
61. L. Fourgeaud et al., Nature 532, 240–244 (2016).
62. R. M. Ransohoff, Nature 532, 185–186 (2016).
63. B. Obermeier, A. Verma, R. M. Ransohoff, Handb. Clin. Neurol.
64. M. Pekny et al., Acta Neuropathol. 131, 323–345 (2016).
65. M. V. Sofroniew, Nat. Rev. Neurosci. 16, 249–263 (2015).
66. K. A. Nave, Nature 468, 244–252 (2010).
K. D. Patel, Brain Res. 1638, 116–128 (2016).
69. Z. Kang et al., Nat. Neurosci. 16, 1401–1408 (2013).
70. K. Bhaskar et al., Neuron 68, 19–31 (2010).
71. R. M. Ransohoff, A. E. Cardona, Nature 468, 253–262 (2010).
72. A. H. Stephan, B. A. Barres, B. Stevens, Annu. Rev. Neurosci.
J. Biol. Chem. 279, 32869–32881 (2004).
76. V. H. Perry, Acta Neuropathol. 120, 277–286 (2010).
77. S. Hong et al., Science 352, 712–716 (2016).
78. P. L. Poliani et al., J. Clin. Invest. 125, 2161–2170 (2015).
79. L. Montalbetti et al., Funct. Neurol. 20, 71–75 (2005).
80. S. Sawcer et al., Nature 476, 214–219 (2011).
81. R. M. Ransohoff, Nat. Immunol. 11, 570–572 (2010).
83. R. M. Ransohoff, B. Engelhardt, Nat. Rev. Immunol. 12, 623–635 (2012).
84. R. B. Banati et al., Brain 123, 2321–2337 (2000).
85. K. A. Nave, Nat. Rev. Neurosci. 11, 275–283 (2010).
86. S. G. Waxman, Trends Mol. Med. 12, 192–195 (2006).
patients rather than globally suppressed.
Institutes of Health, Bethesda, MD 20852, USA.
NOX2 activity exclusively to microglia.
Advancement of Science; all rights reserved. The title Science is a registered trademark of AAAS.
Ce fichier a été mis en ligne par un utilisateur du site. Identifiant unique du document: 00469241.

References: V. 

V. 
 V. 
 V. 
 V. 
 V. 
 V.